Why are CGRP monoclonal antibodies not yet the first line treatment in migraine prevention?
ABSTRACT Migraine is a prevalent disorder and a cause of high disability, influenced by modifiable and non-modifiable risk factors. Comorbid and psychiatric illnesses are prevalent in migraine patients and should be considered when choosing preventive drugs. There have been unforeseen problems with...
Saved in:
| Main Author: | Caio Vinicius de Meira Grava Simioni |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Thieme Revinter Publicações
2022-08-01
|
| Series: | Arquivos de Neuro-Psiquiatria |
| Subjects: | |
| Online Access: | http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0004-282X2022000700214&tlng=en |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Disrupting Migraine Dynamics: A Narrative Review of the Consequences of Modern Anti-CGRP Monoclonal Antibody Therapies
by: Dawn C. Buse, et al.
Published: (2025-05-01) -
Efficacy of monoclonal antibodies against CGRP in migraine patients with fibromyalgia comorbidity: a retrospective monocentric observational study
by: Marina de Tommaso, et al.
Published: (2025-05-01) -
It is time anti-CGRP monoclonal antibodies be considered first-line prophylaxis for migraine
by: Gabriel Taricani Kubota
Published: (2022-08-01) -
Influence of Constipation in the Behavior of Circulating Alpha- and Beta-CGRP Levels in Chronic/High-Frequency Migraine Patients After CGRP Monoclonal Antibodies
by: Gabriel Gárate, et al.
Published: (2025-05-01) -
Prevalence, disability, and economic impact of migraine in Spain: a nationwide population-based study
by: Margarita Sanchez-del-Rio, et al.
Published: (2025-05-01)